Main
|
Note: This record shows only 24 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT00151710 |
Date of registration:
|
08/09/2005 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Effects of Pioglitazone in Congenital Adrenal Hyperplasia
|
Scientific title:
|
Effects of Pioglitazone in Glucocorticoid-Induced Insulin Resistance. Studies in Congenital Adrenal Hyperplasia. |
Date of first enrolment:
|
May 2005 |
Target sample size:
|
|
Recruitment status: |
Completed |
URL:
|
http://clinicaltrials.gov/show/NCT00151710 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind
|
Phase:
|
N/A
|
|
Countries of recruitment
|
Netherlands
| | | | | | | |
Contacts
|
Contact type:
|
|
Name:
|
Cornelis J Tack, MD, PhD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Radboud University |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- biochemical and genetically proven congenital adrenal hyperplasia
- stable corticosteroid replacement for 3 months
Exclusion Criteria:
- age < 18 years
- inability to give informed consent
- significant cardiovascular disease, defined as myocardial infarction or stroke, six
months preceding the study
- significant renal disease, GFR < 30 ml/min
- significant liver disease, defined as more than 3 times upper limit of normal values
of alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
- pregnancy
- mental disease
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Congenital Adrenal Hyperplasia
|
Intervention(s)
|
Drug: Pioglitazone
|
Secondary ID(s)
|
H6E-UT-O013
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available: |
|
URL: |
|
URL of the protocol: |
|
Date Posted: |
|
Date of completion: |
|
Date of first publication: |
|
Results summary: |
|
Baseline characteristics: |
|
Adverse events: |
|
Outcome measures: |
|
IPD sharing plan: |
|
IPD sharing description: |
|
|
|